Sign in8 stories
Three new US patent applications cover LSD, ketamine and ibogaine paired with NeuroThera's PEA technology for conditions including depression, PTSD and substance use disorders.
SEC filing
The approval opens Yale School of Medicine's Department of Psychiatry as a new recruitment site for Parts B and C of the Phase I/II study, following positive Part A safety data.
SEC filing
The clinical-stage biotech will pay $2.5 million for majority control of Charging Robotics and extend a separate $1.5 million loan.
SEC filing
Clearmind Medicine said Part C of its CMND-100 study is one-third enrolled, with three patients dosed at each of two Israeli medical centers.
SEC filing
A newly published U.S. patent application covers combining MDMA with N-acylethanolamines like PEA, as FDA's new psychedelics guidance also names MDMA as a covered drug class.
SEC filing
An independent monitoring board unanimously backed moving Clearmind Medicine's CMND-100 study into Parts B and C after Part A safety data.
SEC filing
The biotech disclosed a non-binding letter of intent to buy a majority stake in an automated-parking wireless charging company for $2.5 million plus a $1.5 million loan.
SEC filing
Yale and Johns Hopkins investigators described an early safety profile with no notable adverse effects in the ongoing Phase I/IIa study of MEAI.
SEC filing